FDA PATIENT REPRESENTATIVE PROGRAM Trademark

Trademark Overview

On Tuesday, January 30, 2018, a trademark application was filed for FDA PATIENT REPRESENTATIVE PROGRAM with the United States Patent and Trademark Office. The USPTO has given the FDA PATIENT REPRESENTATIVE PROGRAM trademark a serial number of 87776021. The federal status of this trademark filing is SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED as of Thursday, January 8, 2026. This trademark is owned by U.S. Department of Health and Human Services. The FDA PATIENT REPRESENTATIVE PROGRAM trademark is filed in the Advertising, Business and Retail Services and Education & Entertainment Services categories with the following description:

Training [ , including distributing course material in connection therewith, ] of patient advocates who will advise the U.S. Food and Drug Administration (FDA) on new and already approved medical products, drugs, biologics, and medical devices, and who provide advice to FDA early in the regulatory medical product development and review process

Recruitment of and promoting the retention of patient advocates who will advise the U.S. Food and Drug Administration (FDA) on new and already approved medical products, drugs, biologics, and medical devices, and who will provide advice to FDA early in the regulatory medical product development and review process
fda patient representative program

General Information

Serial Number87776021
Word MarkFDA PATIENT REPRESENTATIVE PROGRAM
Filing DateTuesday, January 30, 2018
Status702 - SECTION 8 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateThursday, January 8, 2026
Registration Number5707463
Registration DateTuesday, March 26, 2019
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 8, 2019

Trademark Statements

Goods and ServicesTraining [ , including distributing course material in connection therewith, ] of patient advocates who will advise the U.S. Food and Drug Administration (FDA) on new and already approved medical products, drugs, biologics, and medical devices, and who provide advice to FDA early in the regulatory medical product development and review process
Goods and ServicesRecruitment of and promoting the retention of patient advocates who will advise the U.S. Food and Drug Administration (FDA) on new and already approved medical products, drugs, biologics, and medical devices, and who will provide advice to FDA early in the regulatory medical product development and review process
NOT AVAILABLE"PATIENT REPRESENTATIVE PROGRAM"

Classification Information

International Class035 - Advertising; business management; business administration; office functions.
US Class Codes100, 101, 102
Class Status Code6 - Active
Class Status DateThursday, November 8, 2018
Primary Code035
First Use Anywhere DateSaturday, November 30, 1991
First Use In Commerce DateSaturday, November 30, 1991
International Class041 - Education; providing of training; entertainment; sporting and cultural activities.
US Class Codes100, 101, 107
Class Status Code6 - Active
Class Status DateFriday, February 9, 2018
Primary Code041
First Use Anywhere DateSaturday, November 30, 1991
First Use In Commerce DateSaturday, November 30, 1991

Trademark Owner History

Party NameU.S. Department of Health and Human Services
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressBethesda, MD 20892
Party NameU.S. Department of Health and Human Services
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBethesda, MD 208922111
Party NameU.S. Department of Health and Human Services
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBethesda, MD 208922111

Trademark Events

Event DateEvent Description
Friday, February 2, 2018NEW APPLICATION ENTERED
Friday, February 9, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, May 12, 2018ASSIGNED TO EXAMINER
Friday, May 25, 2018NON-FINAL ACTION WRITTEN
Friday, May 25, 2018NON-FINAL ACTION E-MAILED
Friday, May 25, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, November 7, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, November 7, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, November 8, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Saturday, November 10, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 19, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 8, 2019PUBLISHED FOR OPPOSITION
Tuesday, January 8, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 26, 2019REGISTERED-PRINCIPAL REGISTER
Monday, January 4, 2021TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, January 4, 2021TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, January 4, 2021ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, January 4, 2021TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, January 4, 2021TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, January 4, 2021APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, March 26, 2024COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Tuesday, September 23, 2025TEAS SECTION 8 & 15 RECEIVED
Monday, December 29, 2025CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Thursday, January 8, 2026REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Thursday, January 8, 2026NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED

Related Keywords

program representative patient medical will devices biologics products drugs provide early review process